Close Menu

NEW YORK (GenomeWeb) – Invivoscribe Technologies said today that it has released a new CE-marked IVD version of its LeukoStrat CDx FLT3 Mutation Assay, which was approved earlier this year by the US Food and Drug Administration.

The test is the first companion diagnostic for acute myeloid leukemia, and identifies both internal tandem duplication (ITD) and tyrosine kinase domain mutations, including large ITD alterations missed by other NGS-based assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.